Celecoxib
- Generic Name
- Celecoxib
- Brand Names
- Celebrex, Elyxyb, Seglentis
- Drug Type
- Small Molecule
- Chemical Formula
- C17H14F3N3O2S
- CAS Number
- 169590-42-5
- Unique Ingredient Identifier
- JCX84Q7J1L
- Background
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon...
- Indication
Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA). Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.
...
- Associated Conditions
- Acute Pain, Ankylosing Spondylitis (AS), Osteoarthritis (OA), Primary Dysmenorrhoea, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Severe Acute Pain
- Associated Therapies
- -
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
- Conditions
- Interventions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2010-03-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 68
- Registration Number
- NCT00151476
- Locations
- 🇪🇸
Pfizer Investigational Site, Barcelona, Spain
Mechanisms of Human Cutaneous Microcirculation in Healthy Volunteers
- Conditions
- First Posted Date
- 2005-09-09
- Last Posted Date
- 2017-11-01
- Lead Sponsor
- University Hospital, Angers
- Target Recruit Count
- 85
- Registration Number
- NCT00152724
- Locations
- 🇫🇷
Laboratoire de Physiologie et Explorations Vasculaires - CHU Angers, Angers, France
Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis
- Conditions
- Interventions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2021-03-03
- Target Recruit Count
- 4484
- Registration Number
- NCT00141102
- Locations
- 🇬🇧
Pfizer Investigational Site, Wansford, United Kingdom
Comparison Of Celecoxib 200 Mg Bid, Loxoprofen Sodium 60 Mg Tid And Placebo In Low Back Pain In Japan
- Conditions
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2021-03-03
- Target Recruit Count
- 1234
- Registration Number
- NCT00141154
- Locations
- 🇯🇵
Pfizer Investigational Site, Tokyo, Japan
Prevention of Colorectal Sporadic Adenomatous Polyps (PRESAP)
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2008-08-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1561
- Registration Number
- NCT00141193
- Locations
- 🇺🇾
Pfizer Investigational Site, Montevideo, Uruguay
Study Of "Continuous Use" Of Celecoxib Vs. "Usual or Intermittent Use"
- First Posted Date
- 2005-08-31
- Last Posted Date
- 2021-03-29
- Target Recruit Count
- 875
- Registration Number
- NCT00139776
- Locations
- 🇬🇧
Pfizer Investigational Site, Trowbridge, United Kingdom
Cisplatin, CPT-11 and Celecoxib With Radiation Therapy and Surgery for Operable Esophageal Cancer
- Conditions
- Interventions
- First Posted Date
- 2005-08-30
- Last Posted Date
- 2017-09-20
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 35
- Registration Number
- NCT00137852
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
Celebrex Short Versus Long Therapy In Osteoarthritis Of The Knee
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2008-06-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 200
- Registration Number
- NCT00137410
- Locations
- 🇮🇹
Pfizer Investigational Site, Venezia, Italy
Celecoxib (Celebrex) Versus Placebo in Men With Recurrent Prostate Cancer
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2009-12-09
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 85
- Registration Number
- NCT00136487
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Celebrex Low Dose ASA Study Examining the Incidence of Gastroduodenal Ulcers in a Healthy Population
- Conditions
- First Posted Date
- 2005-08-29
- Last Posted Date
- 2021-03-03
- Target Recruit Count
- 605
- Registration Number
- NCT00137033
- Locations
- 🇺🇸
Pfizer Investigational Site, Chesapeake, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.